Testing rimegepant for migraine-time to revise the trial design? - Authors' reply

Lancet. 2020 Jun 20;395(10241):1901-1902. doi: 10.1016/S0140-6736(20)30231-2.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Calcitonin Gene-Related Peptide Receptor Antagonists
  • Humans
  • Migraine Disorders*
  • Piperidines
  • Pyridines

Substances

  • Calcitonin Gene-Related Peptide Receptor Antagonists
  • Piperidines
  • Pyridines
  • rimegepant sulfate